Endocyte Chooses CEO Successor
Executive Summary
Personalised therapy specialist Endocyte Inc. has appointed Mike Sherman president and CEO succeeding founding CEO Ron Ellis, who has resigned. Sherman has been the company’s chief financial officer since 2006, and took on the additional role of chief operating officer in 2014. Prior to this, he held a variety of executive roles, most recently as vice president of finance and strategic planning at Guidant Corporation.
You may also be interested in...
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.
Pipeline Watch: Six Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.